Skip to main content
main-content

Cardiovascular disorders


Browse the latest news, expert commentary, and educational content on cardiovascular disorders.


Highlights

01-06-2021 | Atherosclerosis | News

Prediabetic, high normal HbA1c levels linked to subclinical atherosclerosis risk

The risk for subclinical atherosclerosis among people at low risk for cardiovascular death increases with increasing glycated hemoglobin levels and is raised even at levels below the prediabetes threshold, research shows.

28-05-2021 | Empagliflozin | News

Empagliflozin gets positive CHMP decision for heart failure

Click through to read more on this announcement

17-05-2021 | ACC 2021 | Conference coverage | News

Heart failure benefits of sotagliflozin consistent in preserved ejection fraction

The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on cardiovascular disorders

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits